Pharmaceuticals

Global Biosimilar Monoclonal Antibodies Market Size, Forecasts, And Opportunities

November 24, 2021 by The Business Research Company

Learn about the global biosimilar monoclonal antibodies market through The Business Research Company, which provides information on biosimilar monoclonal antibodies market size, biosimilar monoclonal antibodies market drivers and restraints, biosimilar monoclonal antibodies market players, the COVID-19 impact on the biosimilar monoclonal antibodies market, and more.

Our annual holiday sale is here! Get your discounted market research reports today.

The global biosimilar monoclonal antibodies market is expected to grow from $3.52 billion in 2020 to $4.33 billion in 2021 at a compound annual growth rate (CAGR) of 23%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar monoclonal antibodies market is expected to reach $10.92 billion in 2025 at a CAGR of 26%.

The prevalence of chronic diseases is expected to drive innovation in biosimilar monoclonal antibodies manufacturing, thus driving the market during the forecast period.

Request A Sample For The Global Biosimilar Monoclonal Antibodies Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smph

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products.

Global biosimilar monoclonal antibodies market segments include:

By Type: Synthetic Chemicals, Biopharmaceuticals, Others

By Application: Chronic & Autoimmune Diseases, Oncology, Others

By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

The focus areas for many companies in the biosimilar monoclonal antibodies market has shifted to mergers and acquisitions to acquire more production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities, or to gain access to new markets.

TBRC’s biosimilar monoclonal antibodies market report covers:

Major Market Players: Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2015-20) and ten years forecast (2021-2025-2030)

The Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030 is one of a series of new reports from The Business Research Company that provides biosimilar monoclonal antibodies market overviews, analyzes and forecasts market size, share, biosimilar monoclonal antibodies market players, biosimilar monoclonal antibodies market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s biosimilar monoclonal antibodies market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here is a list of similar reports from The Business Research Company:

Filgrastim Biosimilars Market

Interested to know more about The Business Research Company?

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our Blog: https://blog.tbrc.info/

Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model